Recently, the General Office of the State Council issued “Certain Opinions on Improving Drug Price Formation Mechanisms” to empower pharmaceutical innovation from top-level design. At the same time, overseas licensing of domestically produced innovative drugs continues to “blossom more”. Recently, HISCO and AbbVie of the United States signed an exclusive license agreement, with a total transaction volume of up to 745 million US dollars. Since the beginning of 2026, many domestic pharmaceutical companies such as CSPC Pharmaceutical Group and Cinda Biotech have reached overseas licensing cooperation with multinational giants, and transactions have been implemented intensively and amounts have continued to rise. Industry insiders believe that peak sales of innovative drugs in China are expected to increase, greatly mobilizing the enthusiasm of enterprises. The entire industry has evolved from being driven overseas in the past to being driven by two wheels in domestic and overseas markets, and the prosperity and certainty of the industry will be further strengthened. On the one hand, it will optimize the profit margins of all links in the domestic drug innovation industry chain, and on the other hand, it will further boost domestic demand for innovative drug research and development.

Recently, the General Office of the State Council issued “Certain Opinions on Improving Drug Price Formation Mechanisms” to empower pharmaceutical innovation from top-level design. At the same time, overseas licensing of domestically produced innovative drugs continues to “blossom more”. Recently, HISCO and AbbVie of the United States signed an exclusive license agreement, with a total transaction volume of up to 745 million US dollars. Since the beginning of 2026, many domestic pharmaceutical companies such as CSPC Pharmaceutical Group and Cinda Biotech have reached overseas licensing cooperation with multinational giants, and transactions have been implemented intensively and amounts have continued to rise. Industry insiders believe that peak sales of innovative drugs in China are expected to increase, greatly mobilizing the enthusiasm of enterprises. The entire industry has evolved from being driven overseas in the past to being driven by two wheels in domestic and overseas markets, and the prosperity and certainty of the industry will be further strengthened. On the one hand, it will optimize the profit margins of all links in the domestic drug innovation industry chain, and on the other hand, it will further boost domestic demand for innovative drug research and development.